Article

Liquid Biopsy in Genitourinary Cancers: Circulating Tumor DNA as a Predictive Biomarker for Treatment Selection and Resistance Monitoring

2026-04-27

Abstract excerpt

<h4>Background: </h4> Genitourinary (GU) cancers — encompassing prostate, urothelial, and renal cell carcinomas — collectively represent a leading source of oncologic morbidity and mortality worldwide. Tumor heterogeneity and the dynamic evolution of resistance mechanisms limit the clinical utility of static tissue biopsies, creating an urgent need for real-time, non-invasive biomarkers. Circulating tumor DNA (ctD...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ef89661d-a4a3-5bb2-b3fc-1cecf484c3dd
DOI: 10.20944/preprints202604.1890.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Liquid Biopsy in Genitourinary Cancers: Circulating Tumor DNA as a Predictive Biomarker for Treatment Selection and Resistance MonitoringDOI 10.20944/preprints202604.1890.v1Read

Circulating Tumor DNA in Genitourinary Malignancies: Current Applications and Future PerspectivesSemantic proximity Read

Integrated Plasma and Urinary Cell-free DNA Profiling Enables Noninvasive Molecular Detection from Ta to T4 Bladder CancerSemantic proximity Read

Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancer.Semantic proximity Read

A clinician's handbook for using ctDNA throughout the patient journey.Semantic proximity Read

A Review of Circulating Tumor DNA (ctDNA) and the Liquid Biopsy in Cancer Diagnosis, Screening, and Monitoring Treatment ResponseSemantic proximity Read

The evolving landscape and clinical utility of circulating tumor DNA across the spectrum of urothelial carcinoma: A systematic review and framework for clinical integration.Semantic proximity Read

Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer.Semantic proximity Read

Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial.Semantic proximity Read

Cell-free urine- and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle invasive bladder cancerSemantic proximity Read

Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.Semantic proximity Read

Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling–informed personalized monitoring assaySemantic proximity Read

Liquid Biopsy: Approaches to Dynamic Genotyping in CancerSemantic proximity Read